| Dr Ankit B Shah, MD, MPH | |
|
8401 Connecticut Ave Ste 104, Chevy Chase, MD 20815-5803 | |
| (240) 892-7070 | |
| (240) 248-0606 |
| Full Name | Dr Ankit B Shah |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 14 Years |
| Location | 8401 Connecticut Ave Ste 104, Chevy Chase, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023312576 | NPI | - | NPPES |
| Entity Name | Medstar Heart Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528345378 PECOS PAC ID: 5698932960 Enrollment ID: O20120130000515 |
News Archive
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.
In a new study, National Institutes of Health researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases and that infection affected the country unevenly.
Researchers from Illinois State University, North Carolina State University, University of South Carolina, and University of Maryland published a new paper in the Journal of Marketing that examines the impact of moving nutrition labels, typically placed on the back of product packages, to the front.
› Verified 4 days ago
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000415 |
News Archive
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.
In a new study, National Institutes of Health researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases and that infection affected the country unevenly.
Researchers from Illinois State University, North Carolina State University, University of South Carolina, and University of Maryland published a new paper in the Journal of Marketing that examines the impact of moving nutrition labels, typically placed on the back of product packages, to the front.
› Verified 4 days ago
| Entity Name | Sports & Performance Cardiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033826011 PECOS PAC ID: 6204205867 Enrollment ID: O20221205000532 |
News Archive
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.
In a new study, National Institutes of Health researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases and that infection affected the country unevenly.
Researchers from Illinois State University, North Carolina State University, University of South Carolina, and University of Maryland published a new paper in the Journal of Marketing that examines the impact of moving nutrition labels, typically placed on the back of product packages, to the front.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ankit B Shah, MD, MPH 8401 Connecticut Ave Ste 104, Chevy Chase, MD 20815-5803 Ph: (240) 892-7070 | Dr Ankit B Shah, MD, MPH 8401 Connecticut Ave Ste 104, Chevy Chase, MD 20815-5803 Ph: (240) 892-7070 |
News Archive
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.
In a new study, National Institutes of Health researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases and that infection affected the country unevenly.
Researchers from Illinois State University, North Carolina State University, University of South Carolina, and University of Maryland published a new paper in the Journal of Marketing that examines the impact of moving nutrition labels, typically placed on the back of product packages, to the front.
› Verified 4 days ago
Dr. Rachel Kaiser, MD, MPH Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5454 Wisconsin Ave, Suite 600, Chevy Chase, MD 20815 Phone: 301-942-7600 | |
Dr. Allen A. Nimetz, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5530 Wisconsin Ave, Suite 700, Chevy Chase, MD 20815 Phone: 301-656-5050 Fax: 301-654-4237 | |
Dr. Steve A Burka, MD Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 5530 Wisconsin Ave, #914, Chevy Chase, MD 20815 Phone: 301-654-3803 Fax: 301-654-3808 | |
Dr. Mark A Miller, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 4411 Leland St, Chevy Chase, MD 20815 Phone: 301-496-0815 | |
Dr. Sara Goldkind, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5630 Wisconsin Ave Apt 807, Chevy Chase, MD 20815 Phone: 240-353-0866 | |
Dr. Robert J Marshall, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5530 Wisconsin Ave Ste 700, Chevy Chase, MD 20815 Phone: 301-656-5050 Fax: 301-654-4237 |